Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.
Adrenoleukodystrophy Emerging Therapies
- Lenti D: bluebird bio
- Leriglitazone: Minoryx Therapeutics, S.L.
- MD1003: MedDay Pharmaceuticals
- MGTA-456: Magenta Therapeutics
- OP-101: Orpheris Inc.
- SOM1201: SOM Biotech
Scope of the Report
- The Adrenoleukodystrophy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Adrenoleukodystrophy across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Adrenoleukodystrophy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Adrenoleukodystrophy research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Adrenoleukodystrophy .
1. Report Introduction
2. Adrenoleukodystrophy
2.1. Overview
2.2. History
2.3. Adrenoleukodystrophy Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Adrenoleukodystrophy Diagnosis
2.6.1. Diagnostic Guidelines
3. Adrenoleukodystrophy Current Treatment Patterns
3.1. Adrenoleukodystrophy Treatment Guidelines
4. Adrenoleukodystrophy - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Adrenoleukodystrophy companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Adrenoleukodystrophy Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Adrenoleukodystrophy Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Adrenoleukodystrophy Late Stage Products (Phase-III)
7. Adrenoleukodystrophy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Adrenoleukodystrophy Discontinued Products
13. Adrenoleukodystrophy Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Adrenoleukodystrophy Key Companies
15. Adrenoleukodystrophy Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Adrenoleukodystrophy Unmet Needs
18. Adrenoleukodystrophy Future Perspectives
19. Adrenoleukodystrophy Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email:Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
